SURGEON VIDEOS

View videos of surgeons successfully inserting DEXTENZA.

John Berdahl, MD*
Vance Thompson Vision
Sioux Falls, SD

Cynthia Matossian, MD*
Matossian Eye Associates
Doylestown, PA

Eric D. Donnenfeld, MD*
OCLI / Ophthalmic Consultants of Long Island
Long Island, NY

John Hovanesian, MD*
Harvard Eye Associates
Orange County, CA

Sydney L. Tyson, MD, MPH*
Eye Associates and SurgiCenter of Vineland
Vineland, NJ

Dee Stephenson, MD*
Stephenson Eye Associates
Venice, FL

*Paid consultant providing services to Ocular Therapeutix, Inc.

Handling the insert1

Carefully remove the foam carrier from the foil pouch and transfer to a clean and dry area.

Dry insert dimensions2

~0.55 mm in diameter
and 3 mm in length.

Inserting into the canaliculus

PULL the lid temporally to open the angle of the canaliculus.3

DILATE the punctum thoroughly for both depth and diameter with an ophthalmic dilator. Avoid perforating the canaliculus. If perforation occurs, do not insert DEXTENZA.1,3

DRY the punctal area. DEXTENZA hydrates quickly upon contact with moisture. If DEXTENZA begins to hydrate before fully inserted, discard the product and use a new DEXTENZA.1

INSERT DEXTENZA nasally using blunt (non-toothed) forceps into the canaliculus until the distal end is just below the punctal opening. Excessive squeezing of DEXTENZA may cause deformation.1,3

Physicians rated DEXTENZA
as easy to insert4,5*

*73.6% of physicians in Study 1, 76.4% in Study 2, and 79.6% in Study 3, for treatment of ocular inflammation and pain following ophthalmic surgery, rated DEXTENZA as easy to insert.4,5

 

Once inserted1

DEXTENZA can be visualized by a blue light source (e.g., slit lamp or hand-held blue light) with a yellow filter.

 

STORAGE AND HANDLING

How DEXTENZA is supplied1

DEXTENZA is supplied sterile in a foam carrier within a foil laminate pouch:

  • NDC 70382-204-10 Carton containing 10 pouches (10 inserts)
  • NDC 70382-204-01 Carton containing 1 pouch (1 insert)

Proper storage and handling1

  • Store refrigerated, between 2°C and 8°C (36°F and 46°F). Do not freeze. Protect from light, keep in package until use.
  • Do not use if pouch has been damaged or broken.
  • DEXTENZA is intended for single dose only.

References: 1. DEXTENZA [package insert]. Bedford, MA: Ocular Therapeutix, Inc; 2021. 2. Data on File 00575. Ocular Therapeutix, Inc. 3. Data on File 00846. Ocular Therapeutix, Inc. 4. Watlers T, et al. J Clin Exp Ophthalmol. 2016; 7(4):1-11. 5. Tyson SL, et al. J Cataract Refract Surg.2019;45(2):204-212{erratum in:2019;45(6):895].

  open
  close
full Prescribing Information
IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
DEXTENZA is contraindicated in patients with active corneal, conjunctival or canalicular infections, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella; mycobacterial infections; fungal diseases of the eye, and dacryocystitis.

WARNINGS AND PRECAUTIONS
Intraocular Pressure Increase – Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. Intraocular pressure should be monitored during treatment.

Bacterial Infections – Corticosteroids may suppress the host response and thus increase the hazard for secondary ocular infections. In acute purulent conditions, steroids may mask infection and enhance existing infection.

Viral Infections – Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

Fungal Infections – Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

Delayed Healing – Use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation.

Other Potential Corticosteroid Complications – The initial prescription and renewal of medication order of DEXTENZA should be made by a physician only after examination of the patient with the aid of magnification, such as slit lamp biomicroscopy, and, where appropriate, fluorescein staining. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.

ADVERSE REACTIONS
Ocular Inflammation and Pain Following Ophthalmic Surgery
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: anterior chamber inflammation including iritis and iridocyclitis (10%), intraocular pressure increased (6%), visual acuity reduced (2%), cystoid macular edema (1%), corneal edema (1%), eye pain (1%), and conjunctival hyperemia (1%). The most common non-ocular adverse reaction was headache (1%).

Itching Associated with Allergic Conjunctivitis
The most common ocular adverse reactions that occurred in patients treated with DEXTENZA were: intraocular pressure increased (3%), lacrimation increased (1%), eye discharge (1%), and visual acuity reduced (1%). The most common non-ocular adverse reaction was headache (1%).

INDICATIONS

DEXTENZA is a corticosteroid indicated for:

  • The treatment of ocular inflammation and pain following ophthalmic surgery.
  • The treatment of ocular itching associated with allergic conjunctivitis.

New Indication

DEXTENZA is now approved for the treatment of ocular itching associated with allergic conjunctivitis.

Learn more

x